Pathology and molecular updates in tumors of the prostate

towards a personalized approach

Silvia Gasparrini, Alessia Cimadamore, Roberta Mazzucchelli, Marina Scarpelli, Francesco Massari, Maria Rosaria Raspollini, Andrea B. Galosi, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Treatment planning in patients with prostate neoplasms and prostate cancer (PCa) is generally based on the clinical and pathological molecular markers obtained from prostate needle biopsy and/or radical prostatectomy specimens. Area covered: Pathology of prostate neoplasms is evolving rapidly. Emerging trends include new additions to the 2016 World Health Organization (WHO) tumor classification as well as expanded diagnostic utility of biomarkers and molecular testing in tissue specimens, liquid biopsies and urinary samples, with the following purposes: diagnosis, prognosis and prediction. Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.

Original languageEnglish (US)
Pages (from-to)781-789
Number of pages9
JournalExpert Review of Molecular Diagnostics
Volume17
Issue number8
DOIs
StatePublished - Aug 3 2017

Fingerprint

Molecular Pathology
Prostate
Prostatic Neoplasms
Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Needle Biopsy
Prostatectomy
Biomarkers
Pathology
Biopsy
Therapeutics

Keywords

  • AR-V7
  • Gleason grading
  • intraductal carcinoma of the prostate
  • liquid biopsies
  • prognostic grade grouping
  • Prostate cancer
  • TMPRSS2-ERG
  • urinary biomarkers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Gasparrini, S., Cimadamore, A., Mazzucchelli, R., Scarpelli, M., Massari, F., Raspollini, M. R., ... Montironi, R. (2017). Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Review of Molecular Diagnostics, 17(8), 781-789. https://doi.org/10.1080/14737159.2017.1341314

Pathology and molecular updates in tumors of the prostate : towards a personalized approach. / Gasparrini, Silvia; Cimadamore, Alessia; Mazzucchelli, Roberta; Scarpelli, Marina; Massari, Francesco; Raspollini, Maria Rosaria; Galosi, Andrea B.; Lopez-Beltran, Antonio; Cheng, Liang; Montironi, Rodolfo.

In: Expert Review of Molecular Diagnostics, Vol. 17, No. 8, 03.08.2017, p. 781-789.

Research output: Contribution to journalReview article

Gasparrini, S, Cimadamore, A, Mazzucchelli, R, Scarpelli, M, Massari, F, Raspollini, MR, Galosi, AB, Lopez-Beltran, A, Cheng, L & Montironi, R 2017, 'Pathology and molecular updates in tumors of the prostate: towards a personalized approach', Expert Review of Molecular Diagnostics, vol. 17, no. 8, pp. 781-789. https://doi.org/10.1080/14737159.2017.1341314
Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR et al. Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Review of Molecular Diagnostics. 2017 Aug 3;17(8):781-789. https://doi.org/10.1080/14737159.2017.1341314
Gasparrini, Silvia ; Cimadamore, Alessia ; Mazzucchelli, Roberta ; Scarpelli, Marina ; Massari, Francesco ; Raspollini, Maria Rosaria ; Galosi, Andrea B. ; Lopez-Beltran, Antonio ; Cheng, Liang ; Montironi, Rodolfo. / Pathology and molecular updates in tumors of the prostate : towards a personalized approach. In: Expert Review of Molecular Diagnostics. 2017 ; Vol. 17, No. 8. pp. 781-789.
@article{3132e2bfe4cc4fd2951a09e20736eb6e,
title = "Pathology and molecular updates in tumors of the prostate: towards a personalized approach",
abstract = "Introduction: Treatment planning in patients with prostate neoplasms and prostate cancer (PCa) is generally based on the clinical and pathological molecular markers obtained from prostate needle biopsy and/or radical prostatectomy specimens. Area covered: Pathology of prostate neoplasms is evolving rapidly. Emerging trends include new additions to the 2016 World Health Organization (WHO) tumor classification as well as expanded diagnostic utility of biomarkers and molecular testing in tissue specimens, liquid biopsies and urinary samples, with the following purposes: diagnosis, prognosis and prediction. Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.",
keywords = "AR-V7, Gleason grading, intraductal carcinoma of the prostate, liquid biopsies, prognostic grade grouping, Prostate cancer, TMPRSS2-ERG, urinary biomarkers",
author = "Silvia Gasparrini and Alessia Cimadamore and Roberta Mazzucchelli and Marina Scarpelli and Francesco Massari and Raspollini, {Maria Rosaria} and Galosi, {Andrea B.} and Antonio Lopez-Beltran and Liang Cheng and Rodolfo Montironi",
year = "2017",
month = "8",
day = "3",
doi = "10.1080/14737159.2017.1341314",
language = "English (US)",
volume = "17",
pages = "781--789",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Pathology and molecular updates in tumors of the prostate

T2 - towards a personalized approach

AU - Gasparrini, Silvia

AU - Cimadamore, Alessia

AU - Mazzucchelli, Roberta

AU - Scarpelli, Marina

AU - Massari, Francesco

AU - Raspollini, Maria Rosaria

AU - Galosi, Andrea B.

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Montironi, Rodolfo

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Introduction: Treatment planning in patients with prostate neoplasms and prostate cancer (PCa) is generally based on the clinical and pathological molecular markers obtained from prostate needle biopsy and/or radical prostatectomy specimens. Area covered: Pathology of prostate neoplasms is evolving rapidly. Emerging trends include new additions to the 2016 World Health Organization (WHO) tumor classification as well as expanded diagnostic utility of biomarkers and molecular testing in tissue specimens, liquid biopsies and urinary samples, with the following purposes: diagnosis, prognosis and prediction. Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.

AB - Introduction: Treatment planning in patients with prostate neoplasms and prostate cancer (PCa) is generally based on the clinical and pathological molecular markers obtained from prostate needle biopsy and/or radical prostatectomy specimens. Area covered: Pathology of prostate neoplasms is evolving rapidly. Emerging trends include new additions to the 2016 World Health Organization (WHO) tumor classification as well as expanded diagnostic utility of biomarkers and molecular testing in tissue specimens, liquid biopsies and urinary samples, with the following purposes: diagnosis, prognosis and prediction. Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.

KW - AR-V7

KW - Gleason grading

KW - intraductal carcinoma of the prostate

KW - liquid biopsies

KW - prognostic grade grouping

KW - Prostate cancer

KW - TMPRSS2-ERG

KW - urinary biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85022046958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022046958&partnerID=8YFLogxK

U2 - 10.1080/14737159.2017.1341314

DO - 10.1080/14737159.2017.1341314

M3 - Review article

VL - 17

SP - 781

EP - 789

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 8

ER -